TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16866673

Group type: EXPERIMENTAL
Intervention: Self-assessment scales (verbal, horizontal visual, and faces pain scales)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Observational rating scale
Number of subjects: 129
Study: 12562865

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation (4 g/d of ethyl esters of EPA and DHA)
Number of subjects: 33
Study: 10704612

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemic patients (HC)
Number of subjects: 56

Group type: COMPARATOR
Intervention: O(2)(‐)‐generating mixture xanthine oxidase/hypoxanthine
Number of subjects: 56
Study: 9739907

Group type: EXPERIMENTAL
Intervention: EMLA 5% cream
Number of subjects: 63

Group type: COMPARATOR
Intervention: Xylocaïne 1% infiltration
Number of subjects: 63
Study: 7886548

Group type: EXPERIMENTAL
Intervention: Exchange transfusion therapy (10-15 units of blood)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Exchange transfusion therapy
Number of subjects: 9

Group type: COMPARATOR
Intervention: Matched non-exchanged patients
Number of subjects: 9
Study: 29578385

Group type: EXPERIMENTAL
Intervention: Resisted 20-m sprints
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Assisted 20-m sprints
Number of subjects: 37

Group type: COMPARATOR
Intervention: Unloaded 20-m sprints
Number of subjects: 37
Study: 30024796

Group type: EXPERIMENTAL
Intervention: Standing tables + Point-of-Decision Prompts (PODPs)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Point-of-Decision Prompts (PODPs) only
Number of subjects: 14
Study: 27923980

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study: 24637568

Group type: EXPERIMENTAL
Intervention: ω-3 fatty-acid consumption (MorDHA capsules: 435 mg of docosahexaenoic acid and 65 mg of eicosapentaenoic acid) for 14 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo capsules for 14 months
Number of subjects: 104
Study: 22263927

Group type: EXPERIMENTAL
Intervention: Self-constructed risk scenario
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prefabricated risk scenario
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-message condition
Number of subjects: 0
Study: 20052455

Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (36 supervised 1-hour sessions on a cycle ergometer over 12 weeks)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 100
Study: 18331138

Group type: EXPERIMENTAL
Intervention: High alcohol risk group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Normative group
Number of subjects: 36
Study: 16254727

Group type: EXPERIMENTAL
Intervention: Levofloxacin 600 mg/day for 1 day
Number of subjects: 236

Group type: COMPARATOR
Intervention: Levofloxacin 300 mg/day for 3 days
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Levofloxacin 600 mg for 1 day
Number of subjects: 236
Study: 12354980

Group type: EXPERIMENTAL
Intervention: Percutaneous self-expanding metal stent
Number of subjects: 54

Group type: COMPARATOR
Intervention: Endoscopic polyethylene endoprosthesis
Number of subjects: 54
Study: 10348224

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (1,000 mg and 400 mg, orally at 24-hr intervals for three doses)
Number of subjects: 158
Study: 8954301

Group type: EXPERIMENTAL
Intervention: Asymptomatic cerebral infarction (ACI)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Symptomatic cerebral infarction (SCI)
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Larger infarctions
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Infarctions in the lateral middle cerebral artery (MCA) territory
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Infarctions in the medial MCA territory
Number of subjects: 383
Study: 1748256

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 41
Study: 6293718

Group type: EXPERIMENTAL
Intervention: Cefotaxime administered 30 to 90 minutes preoperatively, every 60 to 90 minutes during surgery, and immediately postoperatively.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cefotaxime or cefazolin administered according to the same regimen as the first group, plus every eight hours for 24 hours postoperatively.
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo (from an earlier study).
Number of subjects: 116
Study: 31831051

Group type: EXPERIMENTAL
Intervention: YH0618 granule (6 g twice a day, 6 days a week, mixed with 300 ml warm water from the first to the fourth chemotherapy cycle)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo granule (same dosage and administration as YH0618)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YH0618 granule
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo granule
Number of subjects: 0
Study: 28317624

Group type: EXPERIMENTAL
Intervention: Cap-Assisted Colonoscopy (CAC)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard Colonoscopy (SC)
Number of subjects: 440
Study: 25335642

Group type: EXPERIMENTAL
Intervention: Chest-worn sleep position trainer (SPT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of SPT + MAD
Number of subjects: 20
Study: 24300821

Group type: EXPERIMENTAL
Intervention: infibeta (Russian Β-interferon-1b biosimilar)
Number of subjects: 123
Study: 20824664

Group type: EXPERIMENTAL
Intervention: CHO diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Saturated fatty acid diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: MUFA diet
Number of subjects: 59
Study: 19415347

Group type: EXPERIMENTAL
Intervention: Ultrasound measures of abdominal muscle activation
Number of subjects: 35
Study: 17223805

Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1 combined with suxamethonium 1 mg.kg‐1 (group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 4 mg.kg‐1 combined with remifentanil 1.25 microg.kg‐1 (group R)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Suxamethonium (group S)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil (group R)
Number of subjects: 60
Study: 15189395

Group type: EXPERIMENTAL
Intervention: Montelukast, a leukotriene receptor antagonist, used in real-world management of asthma
Number of subjects: 400
Study: 11436940

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2% b.i.d. for 2 weeks
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo b.i.d. for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate 0.2%
Number of subjects: 12
Study: 9744711

Group type: EXPERIMENTAL
Intervention: Randomized controlled clinical trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primary systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical evaluation of response to treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomization
Number of subjects: 0
Study: 7831656

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of warfarin (group A)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Gradual withdrawal of warfarin (group B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group A (abrupt withdrawal)
Number of subjects: 32
Study: 3149240

Group type: EXPERIMENTAL
Intervention: Flumazenil 1 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 20
Study: 29630032

Group type: EXPERIMENTAL
Intervention: Perineural dexamethasone 4 mg (1 mL) with 30 mL ropivacaine 0.375%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intravenous dexamethasone 10 mg (2.5 mL) with 30 mL ropivacaine 0.375%
Number of subjects: 100
Study: 28774950

Group type: EXPERIMENTAL
Intervention: Lower-dose aerobic exercise training (33.6 kJ·kg‐1 body weight weekly)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Higher-dose aerobic exercise training (58.8 kJ·kg‐1 body weight weekly)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 72
Study: 26491826

Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23929578

Group type: EXPERIMENTAL
Intervention: Critical appraisal exercises (CA)
Number of subjects: 42
Study: 21677633

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning using an automated thigh tourniquet (three 5-min intervals of ischemia separated by 5-min intervals of reperfusion)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 18270716

Group type: EXPERIMENTAL
Intervention: Whole-body magnetic resonance angiography (WBMRA) with 40 ml gadodiamide
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors (included in FRS)
Number of subjects: 306
Study: 16563559

Group type: EXPERIMENTAL
Intervention: Vinorelbine/Cisplatin (VC regimen) followed by Docetaxel/Gemcitabine (DG regimen)
Number of subjects: 59
Study: 14531480

Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 691

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 691
Study: 11299593

Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (fed by nasogastric jejunal tube Survimed OPD, 30 kcal/kg)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Early jejunal feeding combined with imipenem prophylaxis (Tienam, 2 x 500 mg i.v.)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Conventional parenteral nutrition (Rindex 10, Infusamin S, Intralipid 10%: 30 kcal/kg)
Number of subjects: 181
Study: 8768914

Group type: EXPERIMENTAL
Intervention: Captopril (three times per day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study: 2000752

Group type: EXPERIMENTAL
Intervention: High osmolar contrast media (diatrizoate, Renografin-76)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low osmolar contrast media (ioxaglate, Hexabrix)
Number of subjects: 60
Study: 6391131

Group type: EXPERIMENTAL
Intervention: Intravenous verapamil, 5 to 10 mg/hour for 2 days
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (25 patients with no specific treatment)
Number of subjects: 29
Study: 29913230

Group type: EXPERIMENTAL
Intervention: Laboratory conditions
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Steel Cut oatmeal breakfast
Number of subjects: 32
Study: 27090574

Group type: EXPERIMENTAL
Intervention: Subcutaneous heparin administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous infusion of heparin
Number of subjects: 0
Study: 24740438

Group type: EXPERIMENTAL
Intervention: Enhanced behavioral parent training (STEPP program)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Traditional behavioral parent training (BPT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 80
Study: 24370033

Group type: EXPERIMENTAL
Intervention: Bortezomib combined with bisphosphonates (A group)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bisphosphonates combined with traditional chemotherapy (B group)
Number of subjects: 43
Study: 21358082

Group type: EXPERIMENTAL
Intervention: Triclosan mouthwash (0.03% W/V)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sodium bicarbonate mouth rinse (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Triclosan mouthwash
Number of subjects: 24
Study: 17522615

Group type: EXPERIMENTAL
Intervention: spaghetti+2*DF
Number of subjects: 20

Group type: COMPARATOR
Intervention: barley porridge
Number of subjects: 20
Study: 15964703

Group type: EXPERIMENTAL
Intervention: Nicopass 1.5 mg nicotine lozenge
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12505931

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen with 80% oxygen, balance nitrogen (Group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine oxygen administration with 30% oxygen, balance nitrogen (Group A)
Number of subjects: 100
Study: 10881121

Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 0
Study: 9371353

Group type: EXPERIMENTAL
Intervention: Zidovudine 100 mg oral capsule, administered five times a day for 3 days and a single dose on day 4
Number of subjects: 12

Group type: COMPARATOR
Intervention: Zidovudine 100 mg oral capsule with megestrol acetate 800 mg (40 mg/ml aqueous suspension) administered for 13 days
Number of subjects: 12
Study: 8250430

Group type: EXPERIMENTAL
Intervention: 70% alcohol (A)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Mercurochrome (M)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Alcohol and mercurochrome (AM)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (C)
Number of subjects: 311
Study: 3161531

Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31403367

Group type: EXPERIMENTAL
Intervention: 5% topical minoxidil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 10% topical minoxidil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 31438916

Group type: EXPERIMENTAL
Intervention: SNEA patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: AA patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: HS
Number of subjects: 32
Study: 30012721

Group type: EXPERIMENTAL
Intervention: Informational telephone call about LARC and SARC availability, effectiveness, and safety prior to surgical abortion.
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standardised notification about appointment logistics without contraception information.
Number of subjects: 234
Study: 26683347

Group type: EXPERIMENTAL
Intervention: Positively primed with a positively phrased Pain Catastrophizing Scale (PCS)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Negatively primed with the original Pain Catastrophizing Scale (PCS)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Not primed (control group)
Number of subjects: 168
Study: 24568472

Group type: EXPERIMENTAL
Intervention: Lobaplatin
Number of subjects: 173

Group type: COMPARATOR
Intervention: Pirarubicin hydrochloride
Number of subjects: 173
Study: 23939707

Group type: EXPERIMENTAL
Intervention: Soap provision intervention
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Soap and latrine cleaning materials
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no soap provision)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intervention schools (soap provision)
Number of subjects: 60
Study: 20012563

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with bortezomib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with akt inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with HDAC inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunomodulatory therapy with thalidomide or lenalidomide combined with monoclonal antibodies
Number of subjects: 0
Study: 18975051

Group type: EXPERIMENTAL
Intervention: 100 ml of iopamidol 300 at an injection rate of 3.0 ml/s
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 100 ml of iopamidol 300 at an injection rate of 3.7 ml/s
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 80 ml of iopamidol 370 at an injection rate of 3.0 ml/s
Number of subjects: 30
Study: 16637481

Group type: EXPERIMENTAL
Intervention: Partial-coverage ceramic restorations (PCRs) made of IPS e.max Press, subjected to masticatory fatigue loading and thermal cycling.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group NP (unprepared molars)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group IN (MOD inlay preparation)
Number of subjects: 96
Study: 19771709

Group type: EXPERIMENTAL
Intervention: Hate crime conditions (motivated by race, sexual orientation, or religion)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-hate crime condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with prejudiced attitudes
Number of subjects: 0
Study: 11304641

Group type: EXPERIMENTAL
Intervention: CODAS verapamil PM 200 mg dosed nightly
Number of subjects: 24

Group type: COMPARATOR
Intervention: Immediate‐acting verapamil 80 mg dosed three times daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both medications tested
Number of subjects: 24
Study: 8630717

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg plus pseudoephedrine HCl 60 mg
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 1450287

Group type: EXPERIMENTAL
Intervention: Nicotine-containing gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physostigmine (anticholinesterase inhibitor)
Number of subjects: 0
Study: 2858839

Group type: EXPERIMENTAL
Intervention: Regular interval (RI) group - buprenorphine 0.3 mg IV before anaesthesia, followed by sublingual buprenorphine 0.4 mg 6 hourly postoperatively
Number of subjects: 80

Group type: COMPARATOR
Intervention: On demand (OD) group - meperidine 1 mg/kg on demand in recovery room, followed by ketobemidone 5 mg subcutaneously on demand
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Regular interval (RI) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: On demand (OD) group
Number of subjects: 80
Study: 31340846

Group type: EXPERIMENTAL
Intervention: Active abdominal functional electrical stimulation (FES) for 30 minutes, twice per day, 5 days per week until ICU discharge.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham (control) abdominal functional electrical stimulation for 30 minutes, twice per day, 5 days per week until ICU discharge.
Number of subjects: 20
Study: 29278720

Group type: EXPERIMENTAL
Intervention: Sad mood induction
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Happy mood induction
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Neutral mood induction
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Age interaction with mood
Number of subjects: 91
Study: 26169350

Group type: EXPERIMENTAL
Intervention: CBIT-VoIP
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 20
Study: 25436966

Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 39 °C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 42 °C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) at 43 °C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) leg immersion at 42 °C
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Passive heat loading (PHL) half immersion at 42 °C
Number of subjects: 12
Study: 22146280

Group type: EXPERIMENTAL
Intervention: Low-load core stability exercises
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: High-load sling exercises
Number of subjects: 109

Group type: COMPARATOR
Intervention: General exercises
Number of subjects: 109
Study: 20225533

Group type: EXPERIMENTAL
Intervention: Immunotherapy with subcutaneous injections of Dp and Df extracts
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no immunotherapy)
Number of subjects: 40
Study: 18627266

Group type: EXPERIMENTAL
Intervention: 4 mg annual zoledronate (n = 17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (n = 16)
Number of subjects: 33
Study: 18320144

Group type: EXPERIMENTAL
Intervention: Silver-impregnated EVD catheters
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (standard EVD catheters)
Number of subjects: 39
Study: 15040821

Group type: EXPERIMENTAL
Intervention: Low-magnitude, high-frequency mechanical stimuli (vibration) - 2.0 m/s2 peak to peak, 30 Hz, two 10-minute treatments/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo - standing on placebo devices for the same duration
Number of subjects: 70
Study: 11562748

Group type: EXPERIMENTAL
Intervention: Third-generation aromatase inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Taxanes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with stem cell support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anti-HER2 monoclonal antibody Trastuzumab
Number of subjects: 0
Study: 9265328

Group type: EXPERIMENTAL
Intervention: Randomised clinical trials
Number of subjects: 0
Study: 7945601

Group type: EXPERIMENTAL
Intervention: Thiopental loading intravenously
Number of subjects: 62
Study: 2897172

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 3.0 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 4.5 micrograms/kg
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.5 or 3.0 micrograms/kg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline, 0.03 ml/kg)
Number of subjects: 80
Study: 30630380

Group type: EXPERIMENTAL
Intervention: Conservative fluid management protocol
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 30408255

Group type: EXPERIMENTAL
Intervention: Basophil Activation Test (BAT) with cow's milk extract and major allergens (casein, α-lactalbumin, β-lactoglobulin)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Double-Blind Placebo-Controlled Food Challenge (DBPCFC)
Number of subjects: 86
Study: 27634477

Group type: EXPERIMENTAL
Intervention: Activated carbon nanoparticle lymphatic tracer
Number of subjects: 103

Group type: COMPARATOR
Intervention: Routine radical thyroidectomy
Number of subjects: 103
Study: 28361822

Group type: EXPERIMENTAL
Intervention: Clozapine (200-600 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Risperidone (4-8 mg/day)
Number of subjects: 63